Cargando…

Clinical validity of increased cortical uptake of [(18)F]flortaucipir on PET as a biomarker for Alzheimer’s disease in the context of a structured 5-phase biomarker development framework

PURPOSE: In 2017, the Geneva Alzheimer’s disease (AD) Biomarker Roadmap initiative adapted the framework of the systematic validation of oncological diagnostic biomarkers to AD biomarkers, with the aim to accelerate their development and implementation in clinical practice. With this work, we assess...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wolters, E. E., Dodich, A., Boccardi, M., Corre, J., Drzezga, A., Hansson, O., Nordberg, A., Frisoni, G. B., Garibotto, V., Ossenkoppele, R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8175307/ https://www.ncbi.nlm.nih.gov/pubmed/33547556 http://dx.doi.org/10.1007/s00259-020-05118-w

Ejemplares similares

Clinical validity of increased cortical binding of tau ligands of the THK family and PBB3 on PET as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
por: Chiotis, Konstantinos, et al.
Publicado: (2021)

Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
por: Bischof, Gérard N, et al.
Publicado: (2021)

2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
por: Leuzy, A., et al.
Publicado: (2021)

The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers
por: Ashton, N. J., et al.
Publicado: (2021)

The strategic biomarker roadmap for the validation of Alzheimer’s diagnostic biomarkers: methodological update
por: Boccardi, Marina, et al.
Publicado: (2021)

Parametric methods for [(18)F]flortaucipir PET
por: Golla, Sandeep SV, et al.
Publicado: (2018)

Test–retest repeatability of [(18)F]Flortaucipir PET in Alzheimer’s disease and cognitively normal individuals
por: Timmers, Tessa, et al.
Publicado: (2019)

Unsupervised [(18)F]Flortaucipir cutoffs for tau positivity and staging in Alzheimer’s disease
por: Quattrini, Giulia, et al.
Publicado: (2023)

Associations between quantitative [(18)F]flortaucipir tau PET and atrophy across the Alzheimer’s disease spectrum
por: Timmers, Tessa, et al.
Publicado: (2019)

Non-invasive Standardised Uptake Value for Verification of the Use of Previously Validated Reference Region for [(18)F]Flortaucipir and [(18)F]Florbetapir Brain PET Studies
por: de Vries, Bart M., et al.
Publicado: (2021)

[(18)F]Flortaucipir PET Across Various MAPT Mutations in Presymptomatic and Symptomatic Carriers
por: Wolters, Emma E., et al.
Publicado: (2021)

International consensus on the use of tau PET imaging agent (18)F-flortaucipir in Alzheimer’s disease
por: Tian, Mei, et al.
Publicado: (2022)

Longitudinal Tau PET Using (18)F-Flortaucipir: The Effect of Relative Cerebral Blood Flow on Quantitative and Semiquantitative Parameters
por: Visser, Denise, et al.
Publicado: (2023)

Effect of Shortening the Scan Duration on Quantitative Accuracy of [(18)F]Flortaucipir Studies
por: Tuncel, Hayel, et al.
Publicado: (2021)

Regional [(18)F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer’s disease
por: Wolters, Emma E., et al.
Publicado: (2020)

Head-to-head comparison of relative cerebral blood flow derived from dynamic [(18)F]florbetapir and [(18)F]flortaucipir PET in subjects with subjective cognitive decline
por: Tuncel, Hayel, et al.
Publicado: (2023)

Flortaucipir (tau) PET in LGI1 antibody encephalitis
por: Day, Gregory S., et al.
Publicado: (2021)

Diagnostic value of amyloid-PET and tau-PET: a head-to-head comparison
por: Altomare, Daniele, et al.
Publicado: (2021)

(18)F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes
por: Tsai, Richard M., et al.
Publicado: (2019)

A novel partial volume correction method for accurate quantification of [(18)F] flortaucipir in the hippocampus
por: Wolters, Emma E., et al.
Publicado: (2018)

(18)F-Flortaucipir in TDP-43 associated frontotemporal dementia
por: Smith, R., et al.
Publicado: (2019)

Evaluation of a visual interpretation method for tau‐PET with (18)F‐flortaucipir
por: Sonni, Ida, et al.
Publicado: (2020)

Association of the top 20 Alzheimer's disease risk genes with [(18)F]flortaucipir PET
por: Stage, Eddie, et al.
Publicado: (2022)

Monoamine oxidase binding not expected to significantly affect [(18)F]flortaucipir PET interpretation
por: Wright, Justin P., et al.
Publicado: (2022)

A multicenter comparison of [(18)F]flortaucipir, [(18)F]RO948, and [(18)F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis
por: Leuzy, Antoine, et al.
Publicado: (2021)

Flortaucipir tau PET imaging in semantic variant primary progressive aphasia
por: Makaretz, Sara J, et al.
Publicado: (2018)

Performance of a [(18)F]Flortaucipir PET Visual Read Method Across the Alzheimer Disease Continuum and in Dementia With Lewy Bodies
por: Coomans, Emma M., et al.
Publicado: (2023)

In Vivo (18)F-Flortaucipir PET Does Not Accurately Support the Staging of Progressive Supranuclear Palsy
por: Malpetti, Maura, et al.
Publicado: (2022)

Assessment of Tau Pathology as Measured by (18)F-THK5317 and (18)F-Flortaucipir PET and Their Relation to Brain Atrophy and Cognition in Alzheimer’s Disease
por: Colato, Elisa, et al.
Publicado: (2021)

Hippocampal [(18)F]flortaucipir BP(ND) corrected for possible spill-in of the choroid plexus retains strong clinico-pathological relationships
por: Wolters, Emma E, et al.
Publicado: (2019)

Detection of tau in Gerstmann-Sträussler-Scheinker disease (PRNP F198S) by [(18)F]Flortaucipir PET
por: Risacher, Shannon L., et al.
Publicado: (2018)

Image-level trajectory inference of tau pathology using variational autoencoder for Flortaucipir PET
por: Hong, Jimin, et al.
Publicado: (2022)

Cryo-EM Structures of Chronic Traumatic Encephalopathy Tau Filaments with PET Ligand Flortaucipir
por: Shi, Yang, et al.
Publicado: (2023)

Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition
por: Pontecorvo, Michael J., et al.
Publicado: (2017)

Rates of longitudinal change in (18)F‐flortaucipir PET vary by brain region, cognitive impairment, and age in atypical Alzheimer's disease
por: Phillips, Jeffrey S., et al.
Publicado: (2021)

Head-to-head comparison of tau positron emission tomography tracers [(18)F]flortaucipir and [(18)F]RO948
por: Smith, Ruben, et al.
Publicado: (2019)

MRI and flortaucipir relationships in Alzheimer's phenotypes are heterogeneous
por: Josephs, Keith A., et al.
Publicado: (2020)

[18F]Flortaucipir distinguishes Alzheimer’s disease from progressive supranuclear palsy pathology in a mixed-pathology case
por: Smith, Ruben, et al.
Publicado: (2020)

The Role of 18F-Flortaucipir (AV-1451) in the Diagnosis of Neurodegenerative Disorders
por: Roy, Saswata, et al.
Publicado: (2021)

Clinical utility of FDG PET in Parkinson’s disease and atypical parkinsonism associated with dementia
por: Walker, Zuzana, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_29t5lsfqib2joucpq9diu894b8